Immunome (IMNM) Short Interest Ratio & Short Volume $8.71 +0.08 (+0.93%) Closing price 07/3/2025 03:23 PM EasternExtended Trading$8.85 +0.14 (+1.61%) As of 07/3/2025 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Immunome Short Interest DataImmunome (IMNM) has a short interest of 12.52 million shares, representing 16.30% of the float (the number of shares available for trading by the public). This marks a -5.44% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.3, indicating that it would take 11.3 days of the average trading volume of 890,246 shares to cover all short positions.Current Short Interest12,520,000 sharesPrevious Short Interest13,240,000 sharesChange Vs. Previous Month-5.44%Dollar Volume Sold Short$115.18 millionShort Interest Ratio11.3 Days to CoverLast Record DateJune 15, 2025Outstanding Shares87,010,000 sharesFloat Size76,800,000 sharesShort Percent of Float16.30%Today's Trading Volume441,626 sharesAverage Trading Volume890,246 sharesToday's Volume Vs. Average50% Short Selling Immunome? Sign up to receive the latest short interest report for Immunome and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartIMNM Short Interest Over TimeIMNM Days to Cover Over TimeIMNM Percentage of Float Shorted Over Time Immunome Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/202512,520,000 shares $115.18 million -5.4%16.3%11.3 $9.20 5/31/202513,240,000 shares $117.31 million +4.1%17.2%11.7 $8.86 5/15/202512,720,000 shares $101.76 million -6.8%16.6%11.3 $8.00 4/30/202513,650,000 shares $119.98 million +9.4%17.8%12.4 $8.79 4/15/202512,480,000 shares $92.35 million +12.1%16.6%10.6 $7.40 3/31/202511,130,000 shares $74.90 million +16.9%14.8%10.1 $6.73 3/15/20259,520,000 shares $83.49 million +2.4%12.6%9.8 $8.77 2/28/20259,300,000 shares $87.42 million -0.5%13.4%10.3 $9.40 2/15/20259,350,000 shares $97.24 million +3.1%13.4%9.9 $10.40 1/31/20259,070,000 shares $100.04 million -14.0%13.0%9.1 $11.03 Get the Latest News and Ratings for IMNM and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immunome and its competitors with MarketBeat's FREE daily newsletter. 1/15/202510,540,000 shares $106.56 million +6.8%20.6%13.1 $10.11 12/31/20249,870,000 shares $104.82 million +12.2%19.2%12.5 $10.62 12/15/20248,800,000 shares $110.70 million -10.1%17.2%11.2 $12.58 11/30/20249,790,000 shares $132.65 million -8.3%19.3%12.4 $13.55 11/15/202410,670,000 shares $105.69 million +1.9%21.0%14.3 $9.91 10/31/202410,470,000 shares $120.09 million -4.1%21.4%17.3 $11.47 10/15/202410,920,000 shares $133.01 million -15.2%22.3%16.8 $12.18 9/30/202412,880,000 shares $188.31 million +3.5%26.3%19.8 $14.62 9/15/202412,440,000 shares $198.67 million -6.4%25.4%16.2 $15.97 8/31/202413,290,000 shares $201.74 million +5.9%27.1%16.5 $15.18 8/15/202412,550,000 shares $175.07 million -8.9%25.6%14.5 $13.95 7/31/202413,780,000 shares $212.35 million +2.4%28.1%14.7 $15.41 7/15/202413,460,000 shares $190.59 million No Change27.5%14.1 $14.16 2/29/20242,650,000 shares $64.13 million -31.2%N/A4.2 $24.20 2/15/20243,850,000 shares $86.70 million +12.9%N/A7.1 $22.52 1/31/20243,410,000 shares $56.50 million +71.4%N/A9.2 $16.57 1/15/20241,990,000 shares $26.19 million +8.2%N/A8.7 $13.16 12/31/20231,840,000 shares $19.69 million +171.4%N/A11.1 $10.70 12/15/2023678,100 shares $5.11 million +24.6%N/A5.1 $7.54 11/30/2023544,100 shares $4.06 million +27.1%N/A7.9 $7.46 11/15/2023428,200 shares $3.40 million +96.4%N/A7.4 $7.95 10/31/2023218,000 shares $1.92 million +10.3%N/A4.6 $8.80 10/15/2023197,700 shares $1.78 million -10.3%N/A4.5 $8.99 9/30/2023220,500 shares $1.84 million -3.0%2.9%4.5 $8.35 9/15/2023227,200 shares $1.65 million +5.3%2.7%0.9 $7.26 8/31/2023215,800 shares $1.39 million +0.1%2.6%0.9 $6.45 8/15/2023215,500 shares $1.61 million -11.7%2.6%0.9 $7.45 7/31/2023244,000 shares $1.75 million +17.4%2.9%1 $7.16 7/15/2023207,800 shares $1.61 million +70.9%2.6%0.8 $7.77 6/30/2023121,600 shares $961.86 thousand -14.9%1.5%0.5 $7.91Post-Halving = Profit Season (Here’s How to Win It) (Ad)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.The Most Profitable Phase of Crypto Just Started - PLUS Claim your $10 in Bitcoin 6/15/2023142,900 shares $763.09 thousand -3.1%1.5%5 $5.34 5/31/2023147,500 shares $772.90 thousand +5.9%1.5%4.7 $5.24 5/15/2023139,300 shares $866.45 thousand -30.0%1.5%4.1 $6.22 4/30/2023198,900 shares $952.73 thousand +8.6%2.1%5.6 $4.79 4/15/2023183,200 shares $883.02 thousand +12.6%1.9%4.5 $4.82 3/31/2023162,700 shares $811.87 thousand +25.6%1.7%3.2 $4.99 3/15/2023129,500 shares $609.95 thousand -11.2%1.4%1.5 $4.71 2/28/2023145,800 shares $666.31 thousand +9.3%1.5%1.7 $4.57 2/15/2023133,400 shares $729.70 thousand +0.9%1.4%1.6 $5.47 1/31/2023132,200 shares $699.34 thousand +15.9%1.4%1.7 $5.29 1/15/2023114,100 shares $456.40 thousand +117.8%1.2%1.6 $4.00 12/30/202252,400 shares $115.80 thousand -13.8%0.6%0.9 $2.21 12/15/202260,800 shares $234.08 thousand -20.3%0.6%3.6 $3.85 11/30/202276,300 shares $330.00 thousand +14.1%0.8%5 $4.33 11/15/202266,900 shares $278.30 thousand +43.9%0.7%4 $4.16 10/31/202246,500 shares $202.74 thousand +10.2%0.5%2.3 $4.36 10/15/202242,200 shares $200.87 thousand -8.7%0.4%1.8 $4.76 9/30/202246,200 shares $205.13 thousand +9.7%0.5%1.9 $4.44 9/15/202242,100 shares $214.29 thousand +7.4%0.4%1.2 $5.09 8/31/202239,200 shares $225.01 thousand -0.3%0.4%1.1 $5.74 8/15/202239,300 shares $208.29 thousand -13.8%0.4%1 $5.30 7/31/202245,600 shares $177.16 thousand -13.0%0.5%1 $3.89 7/15/202252,400 shares $205.93 thousand -6.4%0.6%0.9 $3.93 6/30/202256,000 shares $179.76 thousand +12.7%0.6%0.8 $3.21 6/15/202249,700 shares $147.61 thousand -41.0%0.5%0.6 $2.97 5/31/202284,200 shares $327.54 thousand +19.9%0.9%1 $3.89 5/15/202270,200 shares $157.25 thousand -50.3%0.7%0.8 $2.24 4/30/2022141,100 shares $530.54 thousand +76.6%1.5%1.8 $3.76 4/15/202279,900 shares $411.49 thousand -48.0%0.8%1.2 $5.15 3/31/2022153,600 shares $872.45 thousand +16.3%1.6%2.4 $5.68 3/15/2022132,100 shares $516.51 thousand -4.4%1.4%2.3 $3.91 2/28/2022138,200 shares $909.36 thousand +4.5%1.5%2.6 $6.58 2/15/2022132,300 shares $1.06 million -17.4%1.4%1.9 $7.98 1/31/2022160,100 shares $1.43 million -27.2%1.9%1.9 $8.96 1/15/2022219,900 shares $2.35 million -9.4%N/A2.3 $10.67 12/31/2021242,600 shares $3.14 million -16.8%2.8%2.6 $12.96 12/15/2021291,500 shares $4.79 million +33.0%3.4%2.5 $16.44 11/30/2021219,200 shares $4.15 million +0.3%2.6%1.4 $18.95 11/15/2021218,500 shares $3.88 million -6.8%2.6%1.5 $17.78 10/29/2021234,400 shares $5.49 million +10.4%2.8%1.6 $23.44 10/15/2021212,300 shares $3.74 million -18.3%2.5%1.4 $17.61 9/30/2021259,900 shares $6.33 million -7.4%3.1%0.5 $24.35 9/15/2021280,700 shares $6.02 million -14.5%3.4%0.6 $21.45 8/31/2021328,400 shares $4.61 million +70.1%4.0%0.8 $14.03 8/13/2021193,100 shares $2.74 million -5.1%2.2%0.4 $14.19 7/30/2021203,400 shares $3.30 million -3.4%2.3%0.5 $16.22 7/15/2021210,600 shares $3.28 million +0.9%2.4%0.5 $15.58 6/30/2021208,700 shares $3.61 million -8.2%2.3%2.2 $17.30 6/15/2021227,400 shares $3.90 million -6.6%2.5%2.5 $17.15 5/28/2021243,500 shares $5.09 million +4.8%2.8%2.6 $20.92Post-Halving = Profit Season (Here’s How to Win It) (Ad)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.The Most Profitable Phase of Crypto Just Started - PLUS Claim your $10 in Bitcoin 5/14/2021232,400 shares $3.80 million +2.6%2.6%2 $16.33 4/30/2021226,600 shares $6.12 million +18.3%2.7%0.8 $27.03 4/15/2021191,600 shares $5.33 million -19.0%2.4%0.7 $27.83 3/31/2021236,400 shares $7.29 million +20.9%2.9%0.8 $30.84 3/15/2021195,500 shares $5.71 million -9.1%2.5%0.7 $29.20 2/26/2021215,100 shares $8.23 million +199.6%2.7%0.8 $38.24 2/12/202171,800 shares $1.67 million +86.0%0.9%0.3 $23.27 1/29/202138,600 shares $543.87 thousand -4.0%0.5%0.5 $14.09 1/15/202140,200 shares $528.23 thousand No Change0.5%0.7 $13.14 IMNM Short Interest - Frequently Asked Questions What is Immunome's current short interest? Short interest is the volume of Immunome shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 12,520,000 shares of IMNM short. 16.30% of Immunome's shares are currently sold short. Learn More on Immunome's current short interest. What is a good short interest ratio for Immunome? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. IMNM shares currently have a short interest ratio of 11.0. Learn More on Immunome's short interest ratio. Which institutional investors are shorting Immunome? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Immunome: Caption Management LLC, Simplex Trading LLC, and Jefferies Financial Group Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Immunome? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 16.30% of Immunome's floating shares are currently sold short. Is Immunome's short interest increasing or decreasing? Immunome saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 12,520,000 shares, a decline of 5.4% from the previous total of 13,240,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Immunome's float size? Immunome currently has issued a total of 87,010,000 shares. Some of Immunome's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Immunome currently has a public float of 76,800,000 shares. How does Immunome's short interest compare to its competitors? 16.30% of Immunome's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Immunome: Kymera Therapeutics, Inc. (13.86%), Viking Therapeutics, Inc. (26.43%), Crinetics Pharmaceuticals, Inc. (11.55%), Alvotech (1.28%), MoonLake Immunotherapeutics (11.56%), Catalyst Pharmaceuticals, Inc. (7.07%), Immunovant, Inc. (29.05%), HUTCHMED (China) Limited Sponsored ADR (0.26%), Organon & Co. (6.16%), ImmunityBio, Inc. (35.32%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Immunome stock? Short selling IMNM is an investing strategy that aims to generate trading profit from Immunome as its price is falling. IMNM shares are trading up $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Immunome? A short squeeze for Immunome occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of IMNM, which in turn drives the price of the stock up even further. How often is Immunome's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including IMNM, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Kymera Therapeutics Short Interest Data Viking Therapeutics Short Interest Data Crinetics Pharmaceuticals Short Interest Data Alvotech Short Interest Data MoonLake Immunotherapeutics Short Interest Data Catalyst Pharmaceuticals Short Interest Data Immunovant Short Interest Data HUTCHMED Short Interest Data Organon & Co. Short Interest Data ImmunityBio Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:IMNM) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNM Stock Alerts